Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Centella asiatica eye drops are a botanical formulation derived from the *Centella asiatica* (Gotu Kola) plant, primarily used in traditional and complementary medicine for the treatment of glaucoma and other ocular conditions. The extract is standardized to contain active triterpenes, including asiaticoside, madecassoside, asiatic acid, and madecassic acid. These constituents are thought to provide neuroprotective effects to the retinal ganglion cells and improve the structural integrity of the trabecular meshwork. By modulating collagen metabolism and reducing oxidative stress, the extract may facilitate the outflow of aqueous humor and potentially lower intraocular pressure (IOP). While frequently found in polyherbal ophthalmic preparations such as Ophthacare, *Centella asiatica* has been investigated for its individual therapeutic potential in managing glaucomatous damage and promoting overall ocular health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on centella asiatica extract.